Horizon's new Cell free DNA formulated in synthetic matrix reference offers greater compatibility with commonly used cfDNA extraction kits.
15 result(s)
Liquid biopsy holds many advantages over solid tumor testing of cancer patients. It is less invasive for the patient, avoiding the need for surgical biopsy, and has improved levels of sensitivity to detect low frequency somatic driver mutations.
This article briefly describes how our reference standards are produced and the quality control measures to ensure the standards are reliable from batch to batch.
Quality control (QC) is vital for Next-generation sequencing (NGS). Here we discuss best practices that will save you time, money, and headaches.
Isolation of genomic DNA from formalin fixed paraffin embedded (FFPE) tissues is a critical step for molecular diagnostic (MDx) assays. Here we investigate extraction of DNA from FFPE using five comparable methods.
We all know NGS analysis can be difficult to navigate. Not only is the human genome complex, but technical errors can occur throughout the entire workflow – from sample preparation, through sequencing and during analysis.
Precision medicine is defined by the Precision Medicine Initiative as, "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person". It allows doctors to prescribe treatment tailored to the individual patient and allows drug developers to create treatments that are more targeted to those individuals.
Liquid biopsy is fast becoming a realistic clinical diagnostic tool, capable of profiling the molecular makeup of a tumor that aids in choosing the right drug and in monitoring treatment response. Studies for its use in early cancer detection are already underway with promising results.
Acute Myeloid Leukaemia (AML) is a group of blood cancer malignancies that originate from the uncontrolled proliferation of blast cells in the bone marrow and circulating blood1. AML is a relatively rare disorder - representing less than 1% of total cancer cases.
Oxford Gene Technology (OGT), a molecular genetics company who manufacture custom NGS cancer panels and sequencing reagents, used Horizon's formalin compromised DNA (fcDNA) reference standards to validate their SureSeq assay technology.